Business
Porta Sophia is building an online database of prior art pertaining to psychedelics with the goal of improving the flawed psychedelic patent process.
Partnerships between funders and researchers at Johns Hopkins illustrate how companies influence the direction of psychedelic science and the release of research data to the public domain.
Mimosa Therapeutics has created a cultured psilocybin mycelium product called Pearls that can be precisely dosed like synthetic psilocybin, but contains all the mushroom’s compounds.
Retreats, converted ketamine clinics, patient management software, professional associations and other service providers ramp up for Oregon’s psilocybin gold rush.
The NGO Blessings of the Forest is spearheading the new arrangement under the Nagoya Protocol, applying an international treaty to a psychedelic substance for the first time.
The psychedelic compound in toad venom is being used to develop therapies for everything from cluster headaches to chronic depression.
The innovation may be the ethical alternative to the controversial practice of collecting Bufo toad venom.
In an exclusive interview, Doblin discusses MAPS’s goal to raise $150 over the next three years, and their $70 million investment fund with Vine Ventures to help meet that funding goal.
Ketamine clinics, which look like everything from a med spa to an art gallery, are cropping up all over the country, including progressive and wealthy cities such as New York.
BMed, a new Spanish nonprofit that will focus on training psychedelic facilitators and educating the general public, stresses the need for community building in the burgeoning psychedelic revival.
